| Income Statement | 2025-09-27 | 2025-06-28 | 2024-12-28 | 2024-09-28 |
|---|---|---|---|---|
| Net revenues | 327,315 | 321,394 | 348,542 | 345,511 |
| Cost of goods sold | 132,571 | 129,150 | 154,995 | 158,074 |
| Gross profit | 194,744 | 192,244 | 193,547 | 187,437 |
| Research and development | 14,872 | 16,261 | 15,829 | 16,530 |
| Selling, general and administrative | 101,615 | 110,719 | 106,459 | 106,946 |
| Amortization of acquired intangible assets | 11,182 | 11,392 | 12,230 | 12,264 |
| Impairment of intangible assets | 8,584 | - | - | - |
| Total operating expenses | 136,253 | 138,372 | 134,518 | 135,740 |
| Operating income | 58,491 | 53,872 | 59,029 | 51,697 |
| Interest and other expense, net | -7,206 | -8,703 | -9,112 | -6,993 |
| Income before provision for income taxes | 51,285 | 45,169 | 49,917 | 44,704 |
| Provision for income taxes | 12,601 | 11,138 | 12,400 | 10,873 |
| Net income | 38,684 | 34,031 | 37,494 | 33,831 |
| Basic (in shares) | 47,590,000 | 48,111,000 | 50,286,000 | 50,898,000 |
| Basic income (loss) per share (in dollars per share) | 0.81 | 0.71 | 0.75 | 0.66 |
| Diluted (in shares) | 47,664,000 | 48,353,000 | 50,639,000 | 51,240,000 |
| Diluted income (loss) per share (in dollars per share) | 0.81 | 0.7 | 0.74 | 0.66 |
HAEMONETICS CORP (HAE)
HAEMONETICS CORP (HAE)